Loading
A phase 2 trial of Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Replimune, Inc., active and no longer recruiting.
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) is a phase 2 interventional study registered as NCT03767348 by Replimune, Inc., with 340 participants planned, started 2017-09-20 and due to reach its primary completion in 2028-06. Interventions recorded: RP1, nivolumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma. No results are recorded here; the registry entry is the source.
Shares Replimune, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Replimune, Immune checkpoint inhibitors.
Shares Replimune, Melanoma, Immune checkpoint inhibitors.